Elekta AB

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0000163628
SEK
55.85
44.17 (378.37%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

1.14 M

Shareholding (Oct 2022)

FII

0.00%

Held by 1 FIIs

DII

100.0%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

High Debt Company with a Debt to Equity ratio (avg) at times

  • Poor long term growth as Operating profit has grown by an annual rate 0.83% of over the last 5 years
  • High Debt Company with a Debt to Equity ratio (avg) at times
2

Poor long term growth as Operating profit has grown by an annual rate 0.83% of over the last 5 years

 
3

Flat results in Apr 25

4

With ROE of 15.12%, it has a expensive valuation with a 2.02 Price to Book Value

5

Underperformed the market in the last 1 year

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

SEK 16,933 Million (Small Cap)

stock-summary
P/E

13.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

10.45%

stock-summary
Debt Equity

0.45

stock-summary
Return on Equity

15.12%

stock-summary
Price to Book

1.86

Revenue and Profits:
Net Sales:
3,646 Million
(Quarterly Results - Jul 2025)
Net Profit:
106 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
375.32%
0%
375.32%
6 Months
557.83%
0%
557.83%
1 Year
309.46%
0%
309.46%
2 Years
331.27%
0%
331.27%
3 Years
487.28%
0%
487.28%
4 Years
553.22%
0%
553.22%
5 Years
617.87%
0%
617.87%

Elekta AB for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
4.44%
EBIT Growth (5y)
0.83%
EBIT to Interest (avg)
7.67
Debt to EBITDA (avg)
0.93
Net Debt to Equity (avg)
0.41
Sales to Capital Employed (avg)
1.07
Tax Ratio
51.02%
Dividend Payout Ratio
386.91%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
17.18%
ROE (avg)
13.38%
Valuation key factors
Factor
Value
P/E Ratio
13
Industry P/E
Price to Book Value
2.02
EV to EBIT
10.41
EV to EBITDA
8.12
EV to Capital Employed
1.71
EV to Sales
1.26
PEG Ratio
1.17
Dividend Yield
9.64%
ROCE (Latest)
16.38%
ROE (Latest)
15.12%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Oct 2022stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jul'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jul 2025 is -4.68% vs -0.08% in Jul 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jul 2025 is 49.30% vs -70.17% in Jul 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jul'25",
        "Jul'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3,646.00",
          "val2": "3,825.00",
          "chgp": "-4.68%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "363.00",
          "val2": "413.00",
          "chgp": "-12.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "83.00",
          "val2": "83.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-16.00",
          "val2": "-78.00",
          "chgp": "79.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "106.00",
          "val2": "71.00",
          "chgp": "49.30%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "60.90%",
          "val2": "66.70%",
          "chgp": "-0.58%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Apr'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Apr 2025 is -0.57% vs 7.41% in Apr 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Apr 2025 is -81.49% vs 37.92% in Apr 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Apr'25",
        "Apr'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "18,016.00",
          "val2": "18,119.00",
          "chgp": "-0.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "3,514.00",
          "val2": "3,498.00",
          "chgp": "0.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "471.00",
          "val2": "482.00",
          "chgp": "-2.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1,207.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "241.00",
          "val2": "1,302.00",
          "chgp": "-81.49%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "122.90%",
          "val2": "130.40%",
          "chgp": "-0.75%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jul'25 - YoYstock-summary
Jul'25
Jul'24
Change(%)
Net Sales
3,646.00
3,825.00
-4.68%
Operating Profit (PBDIT) excl Other Income
363.00
413.00
-12.11%
Interest
83.00
83.00
Exceptional Items
-16.00
-78.00
79.49%
Consolidate Net Profit
106.00
71.00
49.30%
Operating Profit Margin (Excl OI)
60.90%
66.70%
-0.58%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Jul 2025 is -4.68% vs -0.08% in Jul 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jul 2025 is 49.30% vs -70.17% in Jul 2024

Annual Results Snapshot (Consolidated) - Apr'25stock-summary
Apr'25
Apr'24
Change(%)
Net Sales
18,016.00
18,119.00
-0.57%
Operating Profit (PBDIT) excl Other Income
3,514.00
3,498.00
0.46%
Interest
471.00
482.00
-2.28%
Exceptional Items
-1,207.00
0.00
Consolidate Net Profit
241.00
1,302.00
-81.49%
Operating Profit Margin (Excl OI)
122.90%
130.40%
-0.75%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Apr 2025 is -0.57% vs 7.41% in Apr 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Apr 2025 is -81.49% vs 37.92% in Apr 2024

stock-summaryCompany CV
About Elekta AB stock-summary
stock-summary
Elekta AB
Pharmaceuticals & Biotechnology
Elekta publ AB is a Sweden-based human care company that develops and sells clinical solutions for the treatment of cancer and brain disorder. The Company offers and develops systems for radiation therapy and radio-surgery, as well as software systems that enhance workflow efficiency throughout the entire spectrum of cancer care. The Company has four product areas: Elekta Neuroscience, which develops solutions for the diagnosis and treatment of neurological diseases; Elekta Oncology, which creates clinical solutions for radiation therapy, such as linear accelerators, integrated imaging systems and clinical solutions for patient positioning and immobilization; Elekta Brachytherapy, which is engaged in the treatment of cancer through internal radiation, and Elekta Software, which develops software solutions for patient information, workflow management and treatment planning in oncology. The Company owns the service business of Asesores Electronicos Especializados SA de CV (AEESA).
Company Coordinates stock-summary
Company Details
Kungstensgatan 18, Box 7593 , STOCKHOLM None : 103 93
stock-summary
Tel: 46 8 58725400
stock-summary
Registrar Details